Every 8-K that iRadimed Corporation (IRMD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow IRMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IRMD filings page.
IRADIMED CORP (IRMD) filed an amended current report to correct a technical EDGAR item-tagging error; the underlying second-quarter 2026 results and exhibits are unchanged. Iradimed reported Q2 2026 revenue of $20.5 million, up 0.5% year over year, with GAAP diluted EPS of $0.41 and non-GAAP diluted EPS of $0.46. Net income declined 10% to $5.2 million as gross margin eased to 74% from 78% amid the initial production ramp of the new 3870 MR IV pump. For the first half of 2026, revenue rose to $42.4 million, up 6%, and net income increased 5% to $11.0 million, while free cash flow more than doubled to $13.3 million.
The board declared a regular quarterly cash dividend of $0.20 per share, payable August 28, 2026. Management guided Q3 2026 revenue to $23.0–$24.5 million with GAAP diluted EPS of $0.49–$0.54, and reaffirmed full-year 2026 guidance for revenue of $91.0–$96.0 million and GAAP diluted EPS of $1.90–$2.05, reflecting expectations for a meaningful ramp in the 3870 pump platform and improved second-half gross margin.
IRADIMED CORPORATION reported Q2 2026 revenue of $20.5 million, up 0.5% from the same quarter in 2025, with net income of $5.2 million and GAAP diluted EPS of $0.41, both below the prior-year $5.8 million and $0.45.
For the first six months of 2026, revenue was $42.4 million, up 6% year over year, with net income of $11.0 million and GAAP diluted EPS of $0.86, both higher than 2025. Non-GAAP diluted EPS was $0.46 for Q2 and $0.95 for the first half.
The company emphasized the initial launch and production ramp of its next-generation 3870 MRI-compatible IV infusion pump, record domestic monitor bookings, and gross margins of 74% in Q2 and 75% year-to-date. Operating cash flow was $5.9 million in Q2 and $14.2 million for the first half. IRADIMED declared a regular quarterly cash dividend of $0.20 per share payable August 28, 2026, and reaffirmed full-year 2026 guidance for revenue of $91.0–$96.0 million and GAAP diluted EPS of $1.90–$2.05.
Iradimed Corporation reported the results of its annual stockholder meeting. Stockholders elected Roger Susi, Monty Allen, Joe Kiani, Hilda Scharen-Guivel and James Hawkins to the board of directors. They also ratified RSM US LLP as independent auditor for the fiscal year ending December 31, 2026, and approved an advisory resolution on executive compensation.
IRADIMED CORPORATION reported strong first-quarter 2026 results, with revenue of $22.0 million, up 13% from $19.5 million a year earlier. GAAP diluted EPS reached $0.45, a 22% increase, and non-GAAP diluted EPS was $0.49, up 17%.
Operating income rose to $7.2 million, up 33%, and gross margin improved to 77%. Cash flow from operations nearly doubled to $8.3 million, driving free cash flow of $7.8 million. The company highlighted the commercial launch of its next-generation 3870 MRI-compatible IV infusion pump, citing strong early demand.
The board declared a regular quarterly cash dividend of $0.20 per share, payable May 29, 2026 to shareholders of record on May 15, 2026. Management issued second-quarter 2026 guidance for revenue of $20.0–$21.0 million and reaffirmed full-year 2026 guidance for revenue of $91.0–$96.0 million and GAAP diluted EPS of $1.90–$2.05.
IRADIMED CORPORATION reported record fourth quarter and full-year 2025 results, with revenue of $22.7 million in Q4, up 17%, and full-year revenue of $83.8 million, up 14% from 2024.
Q4 2025 net income rose to $6.4 million, or $0.50 per diluted share, a 25% year-over-year increase, while non-GAAP diluted EPS reached $0.54. For 2025, net income was $22.5 million, or $1.75 per diluted share, with non-GAAP diluted EPS of $1.93.
The board raised the regular quarterly cash dividend to $0.20 per share from $0.17, payable on March 6, 2026 to shareholders of record on February 23, 2026. Management guided 2026 revenue to $91.0–$96.0 million, GAAP diluted EPS of $1.90–$2.05, and non-GAAP diluted EPS of $2.06–$2.21, reflecting expectations for contributions from the next-generation 3870 MRI-compatible IV infusion pump.
IRADIMED CORPORATION filed a Form 8-K to report that it issued a press release on November 3, 2025 announcing its financial results for the quarter ended September 30, 2025.
The press release is furnished as Exhibit 99.1 and is designated as “furnished,” not “filed,” meaning it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other securities filings.
iRadimed Corporation reported the appointment of Mr. Kiani to its board of directors and furnished a related press release as Exhibit 99.1. The board has determined that Mr. Kiani is "financially literate" under Nasdaq rules. The filing states there are no arrangements or understandings between Mr. Kiani and any other person regarding his appointment and that he has no transactions requiring disclosure under Item 404(a) of Regulation S-K. The notice appears limited to the director appointment and required disclosures; it does not provide biographical details, committee assignments, equity holdings, or other background information about Mr. Kiani.
iRadimed held its Annual Meeting of Stockholders on June 19, 2025, where shareholders voted on three key proposals. All proposals passed successfully.
The voting results included:
- Board Elections: Five directors were elected with varying levels of support: - Hilda Scharen-Guivel received highest support (10.8M votes) - Anthony Vuoto (10.8M votes) - Monty Allen (9.5M votes) - Roger Susi (8.9M votes) - James Hawkins (8.4M votes)
- Auditor Ratification: RSM US LLP was confirmed as independent auditor with overwhelming support (11.8M votes in favor)
- Executive Compensation: Advisory resolution on executive compensation approved with strong support (10.8M votes in favor, 287K against)
The meeting demonstrated strong shareholder participation with approximately 11.8M total votes cast, including 709,490 broker non-votes on certain matters.